Compare · BASI vs IQV
BASI vs IQV
Side-by-side comparison of Bioanalytical Systems, Inc. (BASI) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BASI and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV carries a market cap of $38.41B.
- IQV has hit the wire 13 times in the past 4 weeks while BASI has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 0 for BASI).
- Company
- Bioanalytical Systems, Inc.
- IQVIA Holdings Inc.
- Price
- -
- -
- Market cap
- -
- $38.41B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- 2013
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest BASI
- SEC Form RW filed by Bioanalytical Systems, Inc.
- SEC Form 8-K filed by Bioanalytical Systems, Inc.
- Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.
- Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
- Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN
- SEC Form 8-K filed
- Colliers Securities resumed coverage on Bioanalytical Systems with a new price target
- SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units
- Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference
- SEC Form EFFECT filed
Latest IQV
- SEC Form 144 filed by IQVIA Holdings Inc.
- Officer Sherbet Eric sold $1,245,800 worth of shares (5,000 units at $249.16), decreasing direct ownership by 19% to 20,999 units (SEC Form 4)
- Officer Cherofsky Keriann sold $136,827 worth of shares (558 units at $245.21), decreasing direct ownership by 16% to 2,989 units (SEC Form 4)
- Officer Bousbib Ari exercised 156,206 shares at a strike of $78.21, sold $26,092,072 worth of shares (106,279 units at $245.51) and returned $12,217,110 worth of shares to the company (49,927 units at $244.70) (SEC Form 4)
- SEC Form 144 filed by IQVIA Holdings Inc.
- SEC Form 10-Q filed by IQVIA Holdings Inc.
- IQVIA Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IQVIA Reports Second-Quarter 2026 Results
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A